New breast cancer drug combo study pulled before starting
NCT ID NCT06829199
First seen Feb 22, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This study aimed to test whether adding the experimental drug boserolimab to standard treatment (pembrolizumab and chemotherapy) before surgery could help people with high-risk, early-stage triple-negative breast cancer. The goal was to see if the combination was safe and could eliminate all signs of cancer in the breast and lymph nodes removed during surgery. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cheng Kung University Hospital ( Site 0901)
Tainan, 704, Taiwan
-
Optum Care Cancer Center ( Site 0004)
Las Vegas, Nevada, 89102, United States
Conditions
Explore the condition pages connected to this study.